Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Reiners

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|July 18, 2014
The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinomaElena-Daphne Thies, Karina Tanase, Uwe Maeder, et al.
The Journal of Clinical Endocrinology and Metabolism|November 15, 2012
Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patientsFrederik A Verburg, Uwe Mäder, Karina Tanase, et al.
Clinical Endocrinology|November 9, 2011
Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinomaStefanie Diessl, Barbara Holzberger, Uwe Mäder, et al.
The Journal of Clinical Endocrinology and Metabolism|April 26, 2013
Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinomaChristoph Reiners, Johannes Biko, Heribert Haenscheid, et al.
The Journal of Clinical Endocrinology and Metabolism|June 4, 2009
Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adultsPatricia Doyle, Christian Düren, Kai Nerlich, et al.
Endocrine Reviews|September 2, 2011
The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapyScott A Rivkees, Ernest L Mazzaferri, Frederik A Verburg, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 2011
[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinomaStefanie Hahner, Michael C Kreissl, Martin Fassnacht, et al.
The Journal of Clinical Endocrinology and Metabolism|April 10, 2008
[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymesStefanie Hahner, Andrea Stuermer, Michael Kreissl, et al.
Endocrine Journal|November 7, 2014
Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not Calcium-D3 supplementationTatiana A Leonova, Valentina M Drozd, Vladimir A Saenko, et al.
Radiation Research|October 4, 2012
Frequency of transferrin receptor positive reticulocytes (TF-Ret) in blood as an indicator of total-body radiation exposure: a pilot study in nuclear medicine patientsKlaus Hempel, Heribert Haenscheid, Johannes Biko, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
European Journal of Nuclear Medicine and Molecular Imaging|July 18, 2014
The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinomaElena-Daphne Thies, Karina Tanase, Uwe Maeder, et al.
The Journal of Clinical Endocrinology and Metabolism|November 15, 2012
Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patientsFrederik A Verburg, Uwe Mäder, Karina Tanase, et al.
Clinical Endocrinology|November 9, 2011
Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinomaStefanie Diessl, Barbara Holzberger, Uwe Mäder, et al.
The Journal of Clinical Endocrinology and Metabolism|April 26, 2013
Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinomaChristoph Reiners, Johannes Biko, Heribert Haenscheid, et al.
The Journal of Clinical Endocrinology and Metabolism|June 4, 2009
Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adultsPatricia Doyle, Christian Düren, Kai Nerlich, et al.
Endocrine Reviews|September 2, 2011
The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapyScott A Rivkees, Ernest L Mazzaferri, Frederik A Verburg, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 2011
[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinomaStefanie Hahner, Michael C Kreissl, Martin Fassnacht, et al.
The Journal of Clinical Endocrinology and Metabolism|April 10, 2008
[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymesStefanie Hahner, Andrea Stuermer, Michael Kreissl, et al.
Endocrine Journal|November 7, 2014
Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not Calcium-D3 supplementationTatiana A Leonova, Valentina M Drozd, Vladimir A Saenko, et al.
Radiation Research|October 4, 2012
Frequency of transferrin receptor positive reticulocytes (TF-Ret) in blood as an indicator of total-body radiation exposure: a pilot study in nuclear medicine patientsKlaus Hempel, Heribert Haenscheid, Johannes Biko, et al.
Pageof 14